share_log

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A:其他
美股SEC公告 ·  06/07 16:03

Moomoo AI 已提取核心訊息

Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.
Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.
Transcode Therapeutics, Inc.已向美國證券交易委員會提交了一份修正它即將召開的股東年會的確定性代理聲明的修正案,並更正了關於法定人數的錯誤要求。修正案澄清了法定人數將要求出席人數或代理代表的持有表決權的流通股份三分之一以上。這一更正符合公司修正後的章程和特拉華州公司法。年度股東大會定於2024年6月13日在Goodwin Procter LLP的波士頓辦事處舉行。修正案不會更改原代理聲明中的任何其他信息,已經提交代理卡或投票指示的股東除非決定更改票,否則無需採取進一步行動。
Transcode Therapeutics, Inc.已向美國證券交易委員會提交了一份修正它即將召開的股東年會的確定性代理聲明的修正案,並更正了關於法定人數的錯誤要求。修正案澄清了法定人數將要求出席人數或代理代表的持有表決權的流通股份三分之一以上。這一更正符合公司修正後的章程和特拉華州公司法。年度股東大會定於2024年6月13日在Goodwin Procter LLP的波士頓辦事處舉行。修正案不會更改原代理聲明中的任何其他信息,已經提交代理卡或投票指示的股東除非決定更改票,否則無需採取進一步行動。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息